Analyzing Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer
Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
Angela DeMichele, MD, MSCE, coleader of the Breast Cancer Research Program, and director of the Breast Cancer Clinical Trials Unit at the University of Pennsylvania’s Abramson Cancer Center, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
In patients with HER2-positive breast cancer, a multi-agent neoadjuvant chemotherapy regimen can be given to any patient with HER2 expression of 3 or more on immunohistochemistry or who are FISH positive. These patients may also benefit from an adjuvant HER2-directed therapy as well, DeMichele says.
For patients with triple-negative breast cancer (TNBC), there are no selection markers to predict which patients will respond to adjuvant chemotherapy. DeMichele advises that all patients with TNBC be given neoadjuvant chemotherapy to see if they respond.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
